Literature DB >> 30409888

Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson's disease.

Roberto Angel Ortega1,2, Mark Groves3,2, Anat Mirelman4,5,6,7, Roy N Alcalay8, Deborah Raymond3,2, Sonya Elango3,2, Helen Mejia-Santana8, Nir Giladi4,6,7, Karen Marder8,9, Susan B Bressman3,2, Rachel Saunders-Pullman3,2.   

Abstract

Entities:  

Keywords:  Parkinson's disease; genetics; movement disorders; neurogenetics

Mesh：

Substances：

Year:  2018        PMID： 30409888      PMCID： PMC6506381          DOI： 10.1136/jnnp-2018-319364

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.

Authors:  Vicki Shanker; Mark Groves; Gary Heiman; Christina Palmese; Rachel Saunders-Pullman; Laurie Ozelius; Deborah Raymond; Susan Bressman
Journal:  Mov Disord       Date:  2011-05-24       Impact factor: 10.338

2.  Progression in the LRRK2-Asssociated Parkinson Disease Population.

Authors:  Rachel Saunders-Pullman; Anat Mirelman; Roy N Alcalay; Cuiling Wang; Roberto A Ortega; Deborah Raymond; Helen Mejia-Santana; Martha Orbe-Reilly; Brooke A Johannes; Avner Thaler; Laurie Ozelius; Avi Orr-Urtreger; Karen S Marder; Nir Giladi; Susan B Bressman
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

3.  First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.

Authors:  Andreas Puschmann; Elisabet Englund; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Anna-Lena Törnqvist; Stig Rehncrona; Håkan Widner; Zbigniew K Wszolek; Matthew J Farrer; Christer Nilsson
Journal:  Parkinsonism Relat Disord       Date:  2011-12-06       Impact factor: 4.891

4.  Candidate endophenotypes for genetic studies of suicidal behavior.

Authors:  J John Mann; Victoria A Arango; Shelli Avenevoli; David A Brent; Frances A Champagne; Paula Clayton; Dianne Currier; Donald M Dougherty; Fatemah Haghighi; Susan E Hodge; Joel Kleinman; Thomas Lehner; Francis McMahon; Eve K Mościcki; Maria A Oquendo; Ganshayam N Pandey; Jane Pearson; Barbara Stanley; Joseph Terwilliger; Amy Wenzel
Journal:  Biol Psychiatry       Date:  2009-02-07       Impact factor: 13.382

5.  Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Authors:  Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder
Journal:  Mov Disord       Date:  2013-10-15       Impact factor: 10.338
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.